Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
2.600
+0.040 (1.56%)
At close: Jun 29, 2026, 4:00 PM EDT
2.590
-0.010 (-0.38%)
After-hours: Jun 29, 2026, 4:10 PM EDT
Adial Pharmaceuticals Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Adial Pharmaceuticals stock have an average target of 7.00, with a low estimate of 6.00 and a high estimate of 8.00. The average target predicts an increase of 169.23% from the current stock price of 2.60.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Adial Pharmaceuticals stock from 3 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '25 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 2 | 2 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Lucid Capital | Lucid Capital | Buy Initiates $6 | Buy | Initiates | $6 | +130.77% | Jun 15, 2026 |
| Maxim Group | Maxim Group | Buy Maintains $8 | Buy | Maintains | $8 | +207.69% | May 13, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.23
from -11.93
EPS Next Year
-1.53
from -2.23
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | n/a | |
| Avg | n/a | n/a | |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -1.02 | -0.57 | |
| Avg | -2.23 | -1.53 | |
| Low | -3.43 | -2.49 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.